Cost‐effectiveness of biologic response modifiers compared to disease‐modifying antirheumatic drugs for rheumatoid arthritis: A systematic review

This publication has 67 references indexed in Scilit:

• Systematic reviews of economic evaluations: utility or futility?
  Health Economics, 2010
• Cardiovascular Morbidity and Mortality in Rheumatoid Arthritis
  The American Journal of Medicine, 2008
• American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis
  Arthritis Care & Research, 2008
• Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment
  PharmacoEconomics, 2006
• Cost Effectiveness of Tumour Necrosis Factor-?? Inhibitors as First-Line Agents in Rheumatoid Arthritis
  PharmacoEconomics, 2006
• Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis
  Arthritis & Rheumatism, 2005
• Modeling the 5‐year cost effectiveness of treatment strategies including tumor necrosis factor‐blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands
  Arthritis Care & Research, 2004
• Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes
  Arthritis & Rheumatism, 2002
• American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
  Arthritis & Rheumatism, 1995
• Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two
  Arthritis & Rheumatism, 1993